(Q44024472)

29 November 2017

title

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes (English)

1 reference

29 November 2017

0 references

1 reference

1 reference

Heise T

1

1 reference

29 November 2017

Bott S

2

1 reference

29 November 2017

Rave K

3

1 reference

29 November 2017

Dressler A

4

1 reference

29 November 2017

Rosskamp R

5

1 reference

29 November 2017

Heinemann L

6

1 reference

29 November 2017

publication date

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

19

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

490-495

1 reference

Insulin analogues and their potential in the management of diabetes mellitus

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00723.X

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00723.X

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00723.X

Use of human ultralente as the basal insulin component in treatment of patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00723.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00723.X

10.1046/J.1464-5491.2002.00723.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference